{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:09:47Z","timestamp":1790186987807,"version":"4.1.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T00:00:00Z","timestamp":1527724800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.01181","type":"journal-article","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T04:28:48Z","timestamp":1527740928000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":75,"title":["Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment"],"prefix":"10.3389","volume":"9","author":[{"given":"Maria G.","family":"Tektonidou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,5,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"B2","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12016-008-8112-z","article-title":"Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy","volume":"36","author":"Tektonidou","year":"2009","journal-title":"Clin Rev Allergy Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/096120339600500113","article-title":"The significance of anticardiolipin antibodies in patients with lupus nephritis","volume":"5","author":"Abu-Shakra","year":"1996","journal-title":"Lupus"},{"key":"B4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/qjmed\/91.6.401","article-title":"Association of anticardiolipin antibodies with intraglomerular thrombi and renal dysfunction in lupus nephritis","volume":"91","author":"Bhandari","year":"1998","journal-title":"QJM"},{"key":"B5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1053\/j.ajkd.2003.09.011","article-title":"Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis","volume":"43","author":"Moroni","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"B6","first-page":"S121","article-title":"Significance of antiphospholipid antibodies in lupus nephritis","volume":"89","author":"Natejumnong","year":"2006","journal-title":"J Med Assoc Thai"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/ki.1991.155","article-title":"Significance of anti-phospholipid antibodies in patients with lupus nephritis","volume":"39","author":"Frampton","year":"1991","journal-title":"Kidney Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0158076","DOI":"10.1371\/journal.pone.0158076","article-title":"Antiphospholipid antibodies in lupus nephritis","volume":"11","author":"Parodis","year":"2016","journal-title":"PLoS One"},{"key":"B9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3899\/jrheum.100650","article-title":"IgM anti-beta2 glycoprotein I is protective against lupus nephritis and renal damage in systemic lupus erythematosus","volume":"38","author":"Mehrani","year":"2011","journal-title":"J Rheumatol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1681\/ASN.V481499","article-title":"Renal vascular complications of systemic lupus erythematosus","volume":"4","author":"Appel","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0272-6386(12)70258-5","article-title":"Lupus anticoagulant in systemic lupus erythematosus: a clinical and renal pathological study","volume":"20","author":"Farrugia","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S0272-6386(12)80543-9","article-title":"Renal thrombotic microangiopathy in patients with systemic lupus erythematosus and the antiphospholipid syndrome","volume":"20","author":"Hughson","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/ndt\/13.2.296","article-title":"Renal thrombotic microangiopathy in systemic lupus erythematosus: clinical correlations and long-term renal survival","volume":"13","author":"Bridoux","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"B14","doi-asserted-by":"publisher","first-page":"R93","DOI":"10.1186\/ar2736","article-title":"Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: a prospective study of 124 cases","volume":"11","author":"Zheng","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"R12","DOI":"10.1186\/ar4142","article-title":"The spectrum of renal thrombotic microangiopathy in lupus nephritis","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/ki.2012.409","article-title":"Inclusion of renal vascular lesions in the 2003 ISN\/RPS system for classifying lupus nephritis improves renal outcome predictions","volume":"83","author":"Wu","year":"2013","journal-title":"Kidney Int"},{"key":"B17","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/j.1399-0012.2012.01625.x","article-title":"Ten-yr renal allograft survival of patients with antiphospholipid antibody syndrome","volume":"26","author":"Vaidya","year":"2012","journal-title":"Clin Transplant"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1111\/j.1600-6143.2010.03233.x","article-title":"Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies","volume":"10","author":"Canaud","year":"2010","journal-title":"Am J Transplant"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1046\/j.1600-6143.2004.00602.x","article-title":"Significance of anticardiolipin antibodies on short and long term allograft survival and function following kidney transplantation","volume":"4","author":"Forman","year":"2004","journal-title":"Am J Transplant"},{"key":"B20","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/ndt\/gfx353","article-title":"Anticardiolipin antibodies and 12-month graft function in kidney transplant recipients: a prognosis cohort survey","volume":"33","author":"Gauthier","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1111\/j.1600-6143.2011.03696.x","article-title":"Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation","volume":"11","author":"Hadaya","year":"2011","journal-title":"Am J Transplant"},{"key":"B22","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/ajt.12540","article-title":"Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation","volume":"14","author":"Lonze","year":"2014","journal-title":"Am J Transplant"},{"key":"B23","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1136\/ard.49.3.184","article-title":"Renal artery thrombosis and hypertension","volume":"49","author":"Ostuni","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.semnephrol.2011.05.007","article-title":"Imaging for renovascular disease","volume":"31","author":"O\u2019Neill","year":"2011","journal-title":"Semin Nephrol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1136\/ard.62.10.999","article-title":"Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension","volume":"62","author":"Sangle","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.ultrasmedbio.2015.02.009","article-title":"Ultrasonographic evaluation of resistive index and renal artery stenosis in patients with anti-phospholipid syndrome: two distinct mechanisms?","volume":"41","author":"Conti","year":"2015","journal-title":"Ultrasound Med Biol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.autrev.2017.10.016","article-title":"Arterial stenosis in antiphospholipid syndrome: update on the unrevealed mechanisms of an endothelial disease","volume":"17","author":"Harifi","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/rheumatology\/keh490","article-title":"Renal artery stenosis in hypertensive patients with antiphospholipid (Hughes) syndrome: outcome following anticoagulation","volume":"44","author":"Sangle","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/j.1464-410X.1994.tb07137.x","article-title":"Renal vein thrombosis caused by primary antiphospholipid syndrome","volume":"74","author":"Morgan","year":"1994","journal-title":"Br J Urol"},{"key":"B30","first-page":"1929","article-title":"Renal vein thrombosis as first clinical manifestation of the primary antiphospholipid syndrome","volume":"10","author":"Ko","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"B31","first-page":"1181","article-title":"Renal involvement in primary antiphospholipid syndrome","volume":"19","author":"Amigo","year":"1992","journal-title":"J Rheumatol"},{"key":"B32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1681\/ASN.V103507","article-title":"The intrarenal vascular lesions associated with primary antiphospholipid syndrome","volume":"10","author":"Nochy","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"B33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1681\/ASN.V13142","article-title":"Antiphospholipid syndrome nephropathy in systemic lupus erythematosus","volume":"13","author":"Daugas","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.20433","article-title":"Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome","volume":"50","author":"Tektonidou","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B35","first-page":"1983","article-title":"Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS","volume":"35","author":"Tektonidou","year":"2008","journal-title":"J Rheumatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/j.1440-1797.2007.00792.x","article-title":"Prevalence and clinicopathologic findings of antiphospholipid syndrome nephropathy in Thai systemic lupus erythematosus patients who underwent renal biopsies","volume":"12","author":"Cheunsuchon","year":"2007","journal-title":"Nephrology (Carlton)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.reuma.2008.12.011","article-title":"Clinical significance of antiphospholipid syndrome nephropathy (APSN) in patients with systemic lupus erythematosus (SLE)","volume":"5","author":"Miranda","year":"2009","journal-title":"Reumatol Clin"},{"key":"B38","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1177\/0961203310397410","article-title":"Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus","volume":"20","author":"Silvari\u00f1o","year":"2011","journal-title":"Lupus"},{"key":"B39","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.autrev.2015.01.002","article-title":"The relevance of \u201cnon-criteria\u201d clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force report on antiphospholipid syndrome clinical features","volume":"14","author":"Abreu","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B40","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/0961203310395051","article-title":"Task Force on Catastrophic Antiphospholipid Syndrome (APS) and non-criteria APS manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions","volume":"20","author":"Cervera","year":"2011","journal-title":"Lupus"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/S0272-6386(03)00352-4","article-title":"The expanding spectrum of renal diseases associated with antiphospholipid syndrome","volume":"41","author":"Fakhouri","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"B42","first-page":"1063","article-title":"Proliferative glomerulonephritis and primary antiphospholipid syndrome","volume":"27","author":"Abdalla","year":"2006","journal-title":"Saudi Med J"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1093\/ndt\/gfh910","article-title":"Steroid-responsive focal segmental glomerulosclerosis in primary antiphospholipid syndrome with successful pregnancy outcome","volume":"20","author":"Bhowmik","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.2215\/CJN.00460110","article-title":"Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients","volume":"5","author":"Sinico","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1002\/art.21157","article-title":"Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia","volume":"52","author":"Pierangeli","year":"2005","journal-title":"Arthritis Rheum"},{"key":"B46","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1196\/annals.1422.058","article-title":"C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies","volume":"1108","author":"Romay-Penabad","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"B47","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1681\/ASN.V94590","article-title":"CD59 protects glomerular endothelial cells from immune-mediated thrombotic microangiopathy in rats","volume":"9","author":"Nangaku","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1681\/ASN.2014050429","article-title":"Complement factor C4d is a common denominator in thrombotic microangiopathy","volume":"26","author":"Chua","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1177\/0961203310368409","article-title":"Association between anti-beta2 glycoprotein I antibodies and renal glomerular C4d deposition in lupus nephritis patients with glomerular microthrombosis: a prospective study of 155 cases","volume":"19","author":"Shen","year":"2010","journal-title":"Lupus"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1177\/0961203314546022","article-title":"Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies","volume":"23","author":"Romay-Penabad","year":"2014","journal-title":"Lupus"},{"key":"B51","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.4049\/jimmunol.177.7.4794","article-title":"A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways","volume":"177","author":"Ritis","year":"2006","journal-title":"J Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood-2009-01-199117","article-title":"Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies","volume":"114","author":"Seshan","year":"2009","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1177\/0961203314538687","article-title":"Identification and treatment of APS renal involvement","volume":"23","author":"Tektonidou","year":"2014","journal-title":"Lupus"},{"key":"B55","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1191\/0961203303lu461oa","article-title":"Renal involvement in primary antiphospholipid syndrome and its response to immunosuppressive therapy","volume":"12","author":"Korkmaz","year":"2003","journal-title":"Lupus"},{"key":"B56","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.autrev.2015.08.010","article-title":"Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review","volume":"15","author":"Kronbichler","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B57","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1177\/0961203316682098","article-title":"A 3-year follow-up of a patient with acute renal failure caused by thrombotic microangiopathy related to antiphospholipid syndrome: case report","volume":"26","author":"Zhou","year":"2017","journal-title":"Lupus"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1002\/art.23764","article-title":"Prevention of murine antiphospholipid syndrome by BAFF blockade","volume":"58","author":"Kahn","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B59","first-page":"215","article-title":"Effective treatment of antiphospholipid syndrome with plasmapheresis and rituximab","volume":"14","author":"Tsagalis","year":"2010","journal-title":"Hippokratia"},{"key":"B60","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/art.37759","article-title":"A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1177\/0961203316682102","article-title":"Belimumab in primary antiphospholipid syndrome","volume":"26","author":"Yazici","year":"2017","journal-title":"Lupus"},{"key":"B62","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/08916930400008524","article-title":"CTLA4Ig prevents initiation but not evolution of anti-phospholipid syndrome in NZW\/BXSB mice","volume":"37","author":"Akkerman","year":"2004","journal-title":"Autoimmunity"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1097\/MD.0000000000000143","article-title":"Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report","volume":"93","author":"Kronbichler","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00296-017-3686-5","article-title":"Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence","volume":"37","author":"Sciascia","year":"2017","journal-title":"Rheumatol Int"},{"key":"B65","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1136\/annrheumdis-2016-209442","article-title":"Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome","volume":"76","author":"Grenn","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1136\/annrheumdis-2016-210485","article-title":"Monocyte type I interferon signature in antiphospholipid syndrome is related to proinflammatory monocyte subsets, hydroxychloroquine and statin use","volume":"75","author":"van den Hoogen","year":"2016","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01181\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T19:36:51Z","timestamp":1661369811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01181\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,31]]},"references-count":66,"alternative-id":["10.3389\/fimmu.2018.01181"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.01181","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,31]]},"article-number":"1181"}}